# UBS Global Gender Equality UCITS ETF Accum -A- USD (GENE) **Page:** https://fundology.uk/fund/gene · ISIN IE00BDR5GV14 ## At a glance > Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise. As of 13/11/2026, GENE (UBS Global Gender Equality UCITS ETF Accum -A- USD, ISIN IE00BDR5GV14) closed at £21.12 on the London Stock Exchange. Its ongoing charge is 0.20% a year (about £20 on £10,000). Over the five years to 13/11/2026 its total return was +55.8%, or +21.6% after UK CPIH inflation. ## Summary UBS Global Gender Equality UCITS ETF Accum -A- USD is an exchange-traded fund (ETF) from UBS, launched in 2017. It tracks the Solactive Equileap Global Gender Equality 100 Leaders Index. You buy and sell it through a share-dealing account or platform during stock-market hours, like a share. Its ongoing charge is 0.2% a year — about £20 a year on every £10,000 invested, taken from the fund's value rather than billed to you. Income from its investments is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you. Latest close: **£21.12** (13/11/2026). ## Key facts | Fact | Value | |---|---| | Ticker (LSE) | GENE | | ISIN | IE00BDR5GV14 | | Category | Global shares | | Type | ETF | | Provider | UBS | | Tracks | Solactive Equileap Global Gender Equality 100 Leaders Index | | Income | Accumulating | | Ongoing charge | 0.20% a year (£20 per £10,000) | | Fund size | £61.7m | | Launched | 2017 | | Domicile | Ireland | | UK reporting fund status | Yes — on HMRC’s list of reporting funds (list of 02/11/2026); reporting fund since 19/12/2017 | ## Past returns (periods to 13/11/2026) After the fund's ongoing charges. "Income reinvested" is total return; "price only" leaves out income paid out. Real returns are after UK CPIH inflation. | Window | Return | After CPIH inflation | Measured as | |---|---|---|---| | 1 year | +15.62% | +11.53% | income reinvested | | 3 years | +61.27% | +45.70% | income reinvested | | 5 years | +55.84% | +21.65% | income reinvested | Returns: as reported (delayed data). Inflation: UK CPIH, latest month published. ## Calendar-year returns Calendar-year returns of UBS Global Gender Equality UCITS ETF Accum -A- USD in pounds (price, with income reinvested in the fund): 2022 −1.4%, 2023 +11.1%, 2024 +11.6%, 2025 +13.6%; 2026 to 13/11/2026 +15.1%. Returns of UBS Global Gender Equality UCITS ETF Accum -A- USD in pounds (price, with income reinvested in the fund) over the 12 months to 30/09/2026: +10.5%; to 30/09/2025: +11.3%; to 30/09/2024: +18.8%; to 30/09/2023: +6.2%; to 30/09/2022: −0.7%. | Year | Return | After CPIH inflation | Measured as | |---|---|---|---| | 2022 | -1.4% | -9.7% | Price | | 2023 | +11.1% | +6.6% | Price | | 2024 | +11.6% | +7.8% | Price | | 2025 | +13.6% | +9.7% | Price | | 2026 to 13/11/2026 | +15.1% | +11.5% | Price | ## Risk metrics | Window | Volatility | Max drawdown | |---|---|---| | 1 year | 10.83% | -6.56% | | 3 years | 10.97% | -12.82% | | 5 years | 11.99% | -12.82% | ## Largest fall Volatility of UBS Global Gender Equality UCITS ETF Accum -A- USD in pounds, annualised from weekly returns to 13/11/2026: 10.8% over 1 year, 11.0% over 3 years, 12.0% over 5 years. Largest fall in the price of UBS Global Gender Equality UCITS ETF Accum -A- USD since November 2021, in pounds: −12.8% from 31/01/2025 to 11/04/2025. The lowest 12-month return of UBS Global Gender Equality UCITS ETF Accum -A- USD in pounds (price, with income reinvested in the fund) since January 2021 was −5.1% (12 months to 17/06/2022); the highest was +28.5% (12 months to 10/04/2026). On 13/11/2026 the price of UBS Global Gender Equality UCITS ETF Accum -A- USD was at its highest weekly close since November 2021, in pounds. ## Charges compared with similar funds Ongoing charge of UBS Global Gender Equality UCITS ETF Accum -A- USD 0.20% a year. Compared on 14/11/2026, 135 of the 207 other global share funds charge more, 17 the same and 55 less (share classes counted once). ## Charges & eligibility - Ongoing charges figure (OCF): **0.20%** per year (as of 13/11/2026) - Stocks and shares ISA eligible: usually (check with your platform) - SIPP eligible: usually (check with your provider) - ISA and SIPP mean the kind of product usually qualifies under HMRC rules. We do not check each platform’s list — each provider decides which funds it offers. Crypto ETNs have not qualified for a stocks and shares ISA since 06/04/2026, and overseas funds that are not UK-recognised UCITS, such as Swiss ETFs, do not usually qualify. ## Questions people ask **What is the ongoing charge of GENE?** The ongoing charge of GENE is 0.20% a year — about £20 a year on every £10,000 invested, taken from the fund’s value rather than billed to you. Platform and dealing fees are charged separately. Ongoing charge of UBS Global Gender Equality UCITS ETF Accum -A- USD 0.20% a year. Compared on 14/11/2026, 135 of the 207 other global share funds charge more, 17 the same and 55 less (share classes counted once). **What does GENE track?** GENE tracks the Solactive Equileap Global Gender Equality 100 Leaders Index. **Is GENE accumulating or distributing?** GENE is accumulating: income is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you. **What is the ISIN of GENE?** The ISIN of GENE is IE00BDR5GV14. An ISIN identifies one exact share class of a fund; GENE is its ticker on the London Stock Exchange. **What were GENE’s returns in each of the last five years?** Calendar-year returns of GENE in pounds (price, with income reinvested in the fund): 2022 −1.4%, 2023 +11.1%, 2024 +11.6%, 2025 +13.6%; 2026 to 13/11/2026 +15.1%. Past performance is not a guide to future returns. **How has GENE done after inflation?** Over the five years to 13/11/2026 GENE’s total return was +55.8%, or +21.6% after UK CPIH inflation. Past performance is not a guide to future returns. --- We show information. We are not financial advisers, not authorised by the FCA, and never recommend specific investments. Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.